Switching from baricitinib to dupilumab as an advanced-line treatment in pediatric patients with atopic dermatitis: a retrospective cohort study

Ayelet Ollech*, Eran Cohen-Barak, Amir Horev, Efrat Bar-Ilan, Shoshana Greenberger

*Corresponding author for this work

Research output: Contribution to journalLetterpeer-review

1 Scopus citations
Original languageEnglish
Pages (from-to)e130-e132
JournalInternational Journal of Dermatology
Volume63
Issue number7
DOIs
StatePublished - Jul 2024

Keywords

  • JAK inhibitors
  • atopic dermatitis
  • biological treatment
  • dupilumab baricitinib
  • pediatric patients
  • systemic treatment

Cite this